TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28854909
Drug: Supplementation with
Normalized name: Similac For Supplementation with Iron Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation with one tablet of 100 mg feverfew, 100 mg coenzyme Q10 and 112.5 mg magnesium per day for 3 months.
Study: 28855148
Drug: Immediate ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate ivermectin treatment with antiepilepsy drugs (AEDs)
Study: 28855148
Drug: Delayed ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed ivermectin treatment (after 4 months) with antiepilepsy drugs (AEDs)
Study: 28856009
Drug: High water
Normalized name: Dimethicone 1.5 g in 75 mL TOPICAL CREAM [SONATURAL HIGH WATER DRAW SUPER HYDRA BALM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High water intake (1.0 to 1.5 L/day increase)
Study: 28857822
Drug: Protease inhibitor-based
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor-based antiretroviral therapy (ART)
Study: 28857936
Drug: Circumferential anal
Normalized name: Mephitis mephitis anal gland fluid preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential anal RFA using Barrx 60 RFA focal catheters, median duration of treatment 6.5 minutes (range 5-13 minutes).
Study: 28859185
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy (1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles).
Study: 28859185
Drug: Inotuzumab ozogamicin
Normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inotuzumab ozogamicin plus mini-hyper-CVD chemotherapy.
Study: 28859622
Drug: Exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure group (positive for anti-HPA antibody)
Study: 28859622
Drug: Non-exposure group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-exposure group (negative for anti-HPA antibody)
Study: 28859648
Drug: Early palliative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early palliative care (EPC) intervention including in-person outpatient palliative care consultation and telephonic nurse coach sessions with monthly calls.
Study: 28860229
Drug: Indicators of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicators of the appropriateness of oral anticoagulant prescriptions developed from hospital information systems.
Study: 28860229
Drug: Cross-sectional study
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-sectional study to assess the ability of indicators to detect inappropriate oral anticoagulant prescriptions.
Study: 28860342
Drug: CUDC-907 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUDC-907 monotherapy
Study: 28861121
Drug: Tacrolimus 3
Normalized name: Tacrolimus 300 microgram/g cutaneous ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 3 mg daily for 24 weeks
Study: 28862547
Drug: Preembolization as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preembolization as an adjunct to surgery or radiotherapy (second RCT)
Study: 28862877
Drug: Mepolizumab (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (750 mg intravenous dose)
Study: 28864814
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 added to corticosteroids (CSs) and cyclosporine A (CsA) as first-line therapy for cGVHD.
Study: 28866290
Drug: PHiD-CV (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV (2 doses for unprimed, 1 dose for primed)
Study: 28866726
Drug: 6 week
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 week course of antibiotics
Study: 28866726
Drug: 12 week
Normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week course of antibiotics
Study: 28866779
Drug: Live oral
Normalized name: Cholera Vaccine Live Oral
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live oral poliovirus vaccine (OPV)
Study: 28867665
Drug: Oral baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral baclofen (dosage not specified)
Study: 28869617
Drug: Yttrium-90 ibritumomab
Normalized name: yttrium
DrugBank: Yttrium Y-90 (DB13076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yttrium-90 ibritumomab tiuxetan, dosage not specified, duration not specified
Study: 28870611
Drug: TargomiRs (miR-16-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TargomiRs (miR-16-based mimic microRNA) administered via 20 min intravenous infusion either once or twice a week in a traditional 3+3 dose-escalation design in five dose cohorts.
Study: 28873076
Drug: Propofol sedation
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol sedation using electroencephalogram monitoring during a constant level of sedation depth (D0 to D2) performed by trained nurses or physicians after a body-weight-adjusted loading dose.
Study: 28874545
Drug: Immune complexes
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV)
Study: 28874545
Drug: Fc-modified, bispecific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin combined with TIV
Study: 28874669
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response in patient-derived models
Study: 28877684
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation intervention (not specified in detail, but includes nicotine replacement therapy or other cessation aids offered to 42% of smokers)
Study: 28877863
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream, applied three times a week for 16 weeks
Study: 28878005
Drug: Citrate Anticoagulant
Normalized name: ANTICOAGULANT CITRATE DEXTROSE
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citrate Anticoagulant
Study: 28879038
Drug: Functional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional and individualised neuromuscular exercise therapy (ET), 12 weeks, 3 sessions per week supervised by trained physical therapists.
Study: 28879040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium channel blocker (CCB) with angiotensin receptor blocker (ARB)
Study: 28879040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiazide diuretic with angiotensin receptor blocker (ARB)
Study: 28879040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium channel blocker (CCB) with ARB
Study: 28879040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiazide diuretic with ARB
Study: 28880374
Drug: Hydroxycarbamide (HC)
Normalized name: hydroxycarbamide
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydroxycarbamide (HC) treatment
Study: 28881319
Drug: 25mg intravenous
Normalized name: estrogens, conjugated (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg intravenous (IV) cocaine
Study: 28881389
Drug: Subcutaneous immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunoglobulin (SCIg)
Study: 28882117
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire regarding eye diseases awareness and practices
Study: 28882349
Drug: Titanium clip-screw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium clip-screw implant system
Study: 28882565
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium absorption study
Study: 28883932
Drug: 1000 international
Normalized name: Sundance Vitamin D3 1000 International Units Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 international units per day of oral vitamin D
Study: 28884840
Drug: Hydroxycarbamide (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycarbamide (first dose)
Study: 28884840
Drug: Hydroxycarbamide (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycarbamide (chronic therapy)
Study: 28886760
Drug: Transcranial Magnetic
Normalized name: transcranial magnetic stimulator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Magnetic Stimulation (TMS) at 5 Hz, delivered in up to 40 daily sessions to the left dorsolateral prefrontal cortex
Study: 28887375
Drug: Initial IVH
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial IVH volume exceeding 20 mL
Study: 28887751
Drug: Drug-Using, Violence-Exposed,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Using, Violence-Exposed, and Impaired Sex class (n = 53; 14%)
Study: 28889107
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from phosphodiesterase-5 inhibitors (PDE5i) to riociguat
Study: 28889769
Drug: Orsiro biodegradable
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orsiro biodegradable polymer drug-eluting stent (BP-DES)
Study: 28889769
Drug: Xience durable
Normalized name: Ruxience
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xience durable polymer drug-eluting stent (DP-DES)
Study: 28893779
Drug: Ceftolozane-tazobactam 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftolozane-tazobactam 1.5 g every 8 hours (q8h)
Study: 28894606
Drug: Conventional maximum
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Conventional maximum treatment (control)
Study: 28898890
Drug: Pirfenidone, mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirfenidone, mean daily dose of 2,091.1 mg, mean exposure of 122 weeks (SD 98), median exposure of 88 weeks (range >0 to 349 weeks)
Study: 28899363
Drug: LJM716 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LJM716 40 mg/kg QW
Study: 28899517
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment of OSA
Study: 28899517
Drug: Continuous positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous positive airway pressure (CPAP) treatment of OSA
Study: 28900040
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid nebulization (2.8 mol/L)
Study: 28900714
Drug: peginterferon alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon alpha-2a (PEGASYS®, 180 µg/week) plus ribavirin (COPEGUS®, 1000/1200 mg/day in genotypes (GT) 1/4 and 800 mg/day in GT 2/3) for 24-72 weeks
Study: 28902596
Drug: Investigational assay
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational assay for detecting resistance to moxifloxacin at 0.5 μg/mL
Study: 28902596
Drug: Investigational assay
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational assay for detecting resistance to moxifloxacin at 2.0 μg/mL
Study: 28903943
Drug: SGN-CD19B at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGN-CD19B at a dose of 300 μg/kg (3 μg/kg drug equivalents)
Study: 28903943
Drug: SGN-CD19B in
Normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SGN-CD19B in combination with rituximab at a dose of 100 μg/kg (1 μg/kg drug equivalents)
Study: 28905294
Drug: Methyl aminolevulinate
Normalized name: Methyl aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyl aminolevulinate cream (MAL) daylight photodynamic therapy (DL-PDT)
Study: 28905323
Drug: 5-azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-azacitidine (75 mg/m²)
Study: 28911136
Drug: Pork ingestion
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork ingestion (170 g) in the OB group
Study: 28911136
Drug: Pork ingestion
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork ingestion (170 g) in the NW group
Study: 28911136
Drug: Pork ingestion
Normalized name: Pork
DrugBank: Pork (DB10561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pork ingestion (170 g) in the OW group
Study: 28911922
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib 400mg q12h daily combined with gemcitabine and cisplatin (SGC)
Study: 28912376
Drug: BAX 930
Normalized name: BAX 855
DrugBank: Rurioctocog alfa pegol (DB16007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX 930 (recombinant ADAMTS-13) at doses of 5, 20, or 40 U/kg body weight
Study: 28912629
Drug: Multiple spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple spinal manipulations administered in a single session
Study: 28913922
Drug: Hydroxyurea at
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea at maximal tolerated dose (MTD)
Study: 28916953
Drug: 30-mg dexlansoprazole
Normalized name: dexlansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg dexlansoprazole
Study: 28917612
Drug: Thyroid-stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-stimulating hormone level >2.5 mIU/L
Study: 28917612
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of thyroid antibodies
Study: 28917648
Drug: Fluoropyrimidine/bevacizumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine/bevacizumab with or without oxaliplatin (mFOLFOX7 or XELOX) as first line chemotherapy for metastatic colorectal cancer
Study: 28917673
Drug: hsTnT ≥15
Approvals — FDA: no, EMA: no, PMDA: no
Description: hsTnT ≥15 ng/l (n=29) in Group B
Study: 28917673
Drug: BNP ≥550
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNP ≥550 pg/ml (n=10) in Group B
Study: 28918167
Drug: Low muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low muscle mass in combination with low strength
Study: 28919031
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) injection for fluorescence detection of sentinel lymph nodes (SLN)
Study: 28919454
Drug: Abagovomab (anti-idiotypic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abagovomab (anti-idiotypic monoclonal antibody mimicking the CA125 protein) vaccination
Study: 28919776
Drug: Omaveloxolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omaveloxolone (15 mg orally once daily)
Study: 28921872
Drug: Dacomitinib 45
Normalized name: dacomitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib 45 mg/day, orally, continuously
Study: 28922088
Drug: Perfluorohexyloctane, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perfluorohexyloctane, 1 drop, 4 times daily for 6-8 weeks
Study: 28922337
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of the web
Study: 28922466
Drug: Blinatumomab (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (continuous intravenous infusion)
Study: 28923060
Drug: Vitamin-D deficiency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin-D deficiency (<10 ng/ml)
Study: 28923104
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) administration of enadenotucirev
Study: 28923104
Drug: Intratumoral (IT)
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral (IT) injection of enadenotucirev (CRC only)
Study: 28923290
Drug: Liquid formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid formulation of Kaletra (lopinavir/ritonavir)
Study: 28924018
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg daily until cGVHD progression)
Study: 28925027
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) drug levels <200 ng/ml or undetectable desethylchloroquine
Study: 28925027
Drug: Self-administered questionnaires
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaires (MASRI <80% or MMAS-8 <6)
Study: 28925785
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy after four cycles (FCR4)
Study: 28925785
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy at end of treatment (EOT)
Study: 28925785
Drug: Fludarabine, cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cyclophosphamide, and rituximab (FCR) therapy
Study: 28926513
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg phytoSERM
Study: 28926513
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg phytoSERM
Study: 28927372
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate regular medication
Study: 28927372
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more potentially inappropriate medications
Study: 28927372
Drug: Medication needing
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication needing surveillance according to NORGEP-NH
Study: 28927372
Drug: Regular use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular use of psychotropic drugs
Study: 28927372
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate regular medication (females)
Study: 28927372
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more concomitant psychotropic medications (females)
Study: 28927372
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of multiple psychoactive drugs
Study: 28928173
Drug: First-line anti-TB
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line anti-TB treatment
Study: 28928706
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical treatments
Study: 28928789
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) treatment during hospitalization
Study: 28931498
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (regular colonoscopy preparation leaflet)
Study: 28932269
Drug: IBS-D Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBS-D Daily Symptom Diary and Event Log
Study: 28932270
Drug: Open-label rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label rifaximin 550 mg three times daily for 2 weeks
Study: 28932928
Drug: Single 4.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 4.1 mg oral solution dose of ixazomib
Study: 28933971
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 200 mcg
Study: 28933971
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI 200/12.5 mcg
Study: 28933971
Drug: Fp DPI
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fp DPI 500 mcg (250 mcg × 2 inhalations)
Study: 28933971
Drug: FS DPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS DPI 500/50 mcg
Study: 28934680
Drug: Gandotinib (LY2784544),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gandotinib (LY2784544), a potent inhibitor of JAK2 activity
Study: 28935432
Drug: ravidasvir 200
Normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ravidasvir 200 mg QD plus sofosbuvir 400 mg QD for 12 weeks (with or without ribavirin)
Study: 28935452
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (median 4 months, range 2-24 months)
Study: 28935718
Drug: Cooling therapy
Normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate COOLING THERAPY TWIST UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling therapy (prematurely discontinued)
Study: 28936121
Drug: Education intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Education intervention consisting of a two-day seminar and monthly coaching sessions for six months.